The controlling shareholder of weight-loss drug maker Novo Nordisk on Monday stated it’s shopping for a supplier of drug manufacturing for $16.5 billion.
Novo Holdings, the controlling shareholder of Novo Nordisk
NVO,
stated it’s shopping for Catalent
CTLT,
for $16.5 billion in money, or $63.50 per Catalent share, a 16.5% premium to Friday’s shut.
Catalent inventory rose 13% in premarket commerce to $61.48.
The deal is a 39% premium to Catalent’s shut earlier than it introduced a strategic overview.
The deal will see Novo promote three fill-finish websites to Novo Nordisk shortly after the deal closes. Novo Nordisk has been struggling to fulfill demand for its in style injectable weight-loss medication.
Catalent has greater than 50 websites globally.
Catalent investor Elliott Investment Management stated it helps the deal.
Novo Holdings had property of 108 billion on the finish of 2022.
Source web site: www.marketwatch.com
